QTc interval prolongation in patients on long-term methadone maintenance therapy

被引:89
作者
Maremmani, I [1 ]
Pacini, M
Cesaroni, C
Lovrecic, M
Perugi, G
Tagliamonte, A
机构
[1] Univ Pisa, Univ Hosp, PISA SIA Study & Intervent Addict Grp Santa Chiar, NFB,Dept Psychiat, IT-56100 Pisa, Italy
[2] Inst Behav Sci G De Lisio, Carrara, Italy
[3] Assoc Applicat Neurosci Knowledge Social Aims AU, Pietrasanta, LU, Italy
[4] Univ Siena, Dept Neurosci, Pharmacol Sect, I-53100 Siena, Italy
[5] Inst Hlth Republ Slovenia, Ljubljana, Slovenia
关键词
methadone; QTc prolongation; ECG; methadone maintenance;
D O I
10.1159/000081416
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objective: The aim of the present study was to assess the incidence of abnormal QTc interval values in a population of subjects on a long-term methadone maintenance treatment, as a single therapy, and with methadone dosages ranging between 10 and 600 mg/daily (mean +/- SD = 87 +/- 76). Method: Basal ECG recordings were carried out in 83 former heroin addicts on long-term successful methadone maintenance therapy for at least 6 months, while no other known QT-prolonging agent was being administered. Results: Eighty-three percent of the subjects had a more prolonged QT interval than the reference values for persons of the same sex and age. Only 2 patients displayed a QTc interval of >500 ms. No correlation emerged between QTc values and methadone dosages. Conclusion: Patients on long-term methadone maintenance treatment show longer than expected QTc interval values. This data, associated with the finding that methadone is a rather potent inhibitor of HERG potassium channels and that it may induce torsade de pointes in predisposed subjects, supports the recommendation that patients entering methadone treatment (MT) are screened for cardiac risk factors. ECG might be considered in ongoing MT patients especially before starting QT-prolonging medications. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 41 条
[1]   What clinicians should know about the QT interval [J].
Al-Khatib, SM ;
LaPointe, NMA ;
Kramer, JM ;
Califf, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16) :2120-2127
[2]   Myocardial infarction associated with methadone and/or dihydrocodeine [J].
Backmund, M ;
Meyer, K ;
Zwehl, W ;
Nagengast, O ;
Eichenlaub, D .
EUROPEAN ADDICTION RESEARCH, 2001, 7 (01) :37-39
[3]   K(v)LQT1 and IsK (minK) proteins associate to form the I-Ks cardiac potassium current [J].
Barhanin, J ;
Lesage, F ;
Guillemare, E ;
Fink, M ;
Lazdunski, M ;
Romey, G .
NATURE, 1996, 384 (6604) :78-80
[4]  
Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
[5]   K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation [J].
Clancy, CE ;
Kurokawa, J ;
Tateyama, M ;
Wehrens, XHT ;
Kass, RS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 :441-461
[6]   Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death [J].
Clancy, CE ;
Rudy, Y .
CARDIOVASCULAR RESEARCH, 2001, 50 (02) :301-313
[7]  
Cubeddu Luigi X, 2003, Am J Ther, V10, P452, DOI 10.1097/00045391-200311000-00013
[8]   QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience [J].
De Ponti, F ;
Poluzzi, E ;
Montanaro, N .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) :1-18
[9]  
Eap C. B., 1999, HEROIN ADDICT REL CL, V1, P19
[10]  
ElSherif N, 1997, CIRCULATION, V96, P4392